Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making. When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. AD biopathologic processes develop over decades before symptoms manifest; this period is increasingly targeted in research as an opportunity to best delay or prevent AD dementia.

What this study adds

Evidence grade: Low

This is a narrative review. This review states that Alzheimer's disease management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making, and that combined pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. Alzheimer's disease biopathologic processes develop over decades before symptoms manifest, and this period is increasingly targeted in research as an opportunity to best delay or prevent Alzheimer's disease dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Atri, A. (2019). The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. The Medical clinics of North America. https://doi.org/10.1016/j.mcna.2018.10.009

Vancouver

Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. The Medical clinics of North America. 2019. doi:10.1016/j.mcna.2018.10.009. PMID: 30704681.

BibTeX

@article{atri2019-30704681,
  author  = {Atri, A.},
  title   = {{The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management}},
  journal = {The Medical clinics of North America},
  year    = {2019},
  doi     = {10.1016/j.mcna.2018.10.009},
  pmid    = {30704681},
  url     = {https://doi.org/10.1016/j.mcna.2018.10.009}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review states that Alzheimer's disease management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making, and that combined pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. Alzheimer's disease biopathologic processes develop over decades before symptoms manifest, and this period is increasingly targeted in research as an opportunity to best delay or prevent Alzheimer's disease dementia.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 54 of 100.54 of 100 points earned46 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Medical clinics of North America)
Journal's citation record 2 / 4 Medical Clinics of North America: journal h-index 161 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 621 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 69.0 citations a year over 9 year(s) since 2019
Impact for its field and year 5 / 6 Cited 34.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 13 other studies in this library
Still being cited 4 / 4 Cited 301 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Alireza Atri: h-index 49 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30704681)
Free to read 0 / 2 Behind a paywall — scores zero
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 47.

Later studies that cite this one

13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also in Getting a diagnosis

141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →